Select Page
Office Location:
Suite 562
Hillman Cancer Center

Mailing address:
5150 Centre Avenue
Pittsburgh, PA 15232


Phone: 412-623-7277

Tess Dujmic

Other Affiliations:
Hillman Cancer Center Cancer Therapeutics Program, Pittsburgh Sarcoma Research Collaborative (PSaRC)


Melissa A. Burgess, MD

Assistant Professor of Medicine (Hematology/Oncology)
University of Pittsburgh School of Medicine

Research Interests

Dr. Burgess is a medical oncologist specializing in bone and soft tissue sarcomas. She is also a clinical and translational scientist with active involvement in clinical trials. Dr. Burgess’ research efforts include clinical trial design, drug development, and translational research of bone and soft tissue sarcomas. She has a special interest in immunotherapeutic approaches including PD-1 pathway inhibition. Dr. Burgess co-led SARC 028, a multicenter phase II trial through the Sarcoma Alliance for Research through Collaboration (SARC) with pembrolizumab in select soft tissue and bone sarcomas, and led translation correlative research trying to identify biomarkers of response to PD-1 inhibition in soft tissue sarcomas. Her current research interests include further elucidating potential biomarkers of response to PD-1 inhibition and testing the hypothesis in a clinical trial for patients with molecularly selected soft tissue sarcoma subtypes using immune checkpoint blockade in combination with targeted agents. Dr. Burgess will lead a national phase II clinical trial sponsored by SARC with funding provided by Merck Investigator Studies Program (MISP).

Technique Expertise or Resources to share

Clinical trials


Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma, Immunotherapy